Transform how you analyse drug development risk
With the only transparent analysis of drug development risk at the product level.
LONDON, BOSTON, TOKYO, SAN FRANCISCO (December 6, 2017) — The upward momentum seen in the pharma and biotech sectors during 2017 looks set to continue into 2018, with more novel medicines set to hit the market and investor support for the industry remaining strong. According to EP Vantage, the editorial arm of Evaluate Ltd., the current business friendly stance at the FDA is unlikely to change next year, while M&A could see an uptick, driven by big pharma and big biotech’s need to re-stock pipelines and U.S. tax reforms.
The coming year will also test the commercial expectations that have been hung on novel therapies like CAR-T and gene therapy, which are being launched into increasingly of cost-sensitive markets. Important clinical read-outs from the field of immuno-oncology, where asset values remain very high, will be closely watched - all of which will help set the tone for investors throughout the year.
“Venture capital funds are very well stocked going into 2018, and both public and private investors look set to remain supportive of innovative, early-stage drug developers,” says Amy Brown, report author. “However there is evidence that expectations have got ahead of themselves in certain areas – particularly in immuno-oncology. To keep investors on side next year the industry needs to deliver some big pipeline wins, and important new drug launches need to perform.”
“Pharma & Biotech 2018 Preview”- Analysis Highlights:
The report can be downloaded at www.evaluategroup.com/PharmaBiotech2018Preview.
Evaluate provides trusted commercial intelligence for the pharmaceutical and medical device industries.
Our EvaluatePharma® online subscription services provides a seamless view of the past, present and future of the global pharmaceutical market in a single, standardised platform.
Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into the current and future developments in the industry.
Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com.